system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Acute Kidney Injury, Adolescent, Adult, Cohort Studies, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Drug Labeling, Exenatide, Female, Humans, Incidence, Male, Middle Aged, Peptides, Proportional Hazards Models, Pyrazines, Retrospective Studies, Risk Assessment, Sitagliptin Phosphate, Triazoles, Venoms, Young Adult.
user
Are exenatide and sitagliptin associated with increased risk of acute renal failure : a retrospective claims analysis? Context: This study evaluated whether the risk of acute renal failure (ARF) increases with exenatide and sitagliptin use. A retrospective cohort study of a large medical and pharmacy claims database was performed. Data for 4 91 539 patients were analysed. Cox proportional hazard models were used to compare the risk of ARF between diabetic and non-diabetic subjects and between diabetic patients treated with exenatide, sitagliptin and control medications. Adjusted Cox analyses showed diabetic subjects had a higher risk of ARF [HR 1.51, confidence interval (CI) 1.26-1.81, p < 0.001] than non-diabetic controls. Compared with diabetic controls, neither exenatide (HR 0.77, CI 0.42-1.41, p = 0.40) nor sitagliptin (HR 1.17, CI 0.82-1.65, p = 0.39) increased the risk of ARF.
assistant
Our study revealed an increased incidence of ARF in diabetic versus non-diabetic patients but no association between use of exenatide or sitagliptin and ARF. Because of the limitations of this observational analysis, we cannot exclude the possibility of a very small increased risk. Final Decision: no